GARY PATOU - 22 Nov 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
22 Nov 2024
Net transactions value
-$200,978
Form type
4
Filing time
22 Nov 2024, 19:48:02 UTC
Previous filing
05 Jun 2024
Next filing
06 Jun 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $25,830 +3,500 +15% $7.38 27,073 22 Nov 2024 Direct
transaction XENE Common Shares Tax liability $25,830 -649 -2.4% $39.80 26,424 22 Nov 2024 Direct F1
transaction XENE Common Shares Sale $117,205 -2,851 -11% $41.11 23,573 22 Nov 2024 Direct
transaction XENE Common Shares Options Exercise $41,599 +3,086 +13% $13.48 26,659 22 Nov 2024 Direct
transaction XENE Common Shares Tax liability $41,631 -1,046 -3.9% $39.80 25,613 22 Nov 2024 Direct F1
transaction XENE Common Shares Sale $83,742 -2,040 -8% $41.05 23,573 22 Nov 2024 Direct
holding XENE Common Shares 4,902 22 Nov 2024 See Note F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3,500 -100% $0.000000 0 22 Nov 2024 Common Shares 3,500 $7.38 Direct F3
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -3,086 -100% $0.000000 0 22 Nov 2024 Common Shares 3,086 $13.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the closing price of the Company's common shares on November 21, 2024 for purposes of net settlement calculations.
F2 By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
F3 The shares subject to the option are fully vested and exercisable.